Since Amgen (http://www.chemdrug.com/company/) first announced the clinical results of KRAS inhibitors at this year's ASCO annual meeting, research and development activities in this field have continued.

 

 

In July this year, Novartis reached a cooperation with mirati company to develop a combination therapy of KRAS inhibitors.

 

 

At present, Cancer Research UK has more than 30 drugs under research (http://www.chemdrug.com/), including 2 drugs in phase 3 clinical stage and 5 drugs approved for marketing.

 

 

 

As one of the most frequently mutated oncogenes in cancer, ras gene family is also an important target developed by researchers of the Beatson Institute of cancer research center in the UK.

 

 

According to the terms of the agreement, Novartis will pay the advance payment of this cooperation to the CRT pioneer Fund (CPF) foundation of 6ec, and provide the research and development funds of KRAS inhibitors to the Beatson Institute.

 

 

Novartis will be entitled to the exclusive authorization of the cooperative drug development, and CPF foundation will also be entitled to the potential milestone payment and future sales share of the cooperative drug development.